OOIR: Observatory of International Research

Papers

(The TQCC of Altex-Alternatives to Animal Experimentation is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Alternative Methods in Science: Towards Fluidic Systems	61
Application of high-throughput transcriptomics for mechanism-based biological read-across of short-chain carboxylic acid analogues of valproic acid_suppl1	37
Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo_suppl1	32
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl1	25
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl5	21
Sensitivity analysis and quality indicators for an in vitro oral irritation assay	12
The effect of surfactants and film-forming polymers on pulmonary surfactant function measured in vitro is dose rate dependent_suppl	11
Validation of an Endopep-suspension immunoassay for the diagnostics of human botulism_suppl	11
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency	11
Animal research ethics as interaction of research ethics, animal ethics, and (animal protection) law	10
Validation of the monocyte activation test with three therapeutic monoclonal antibodies	9
REACH out-numbered! The future of REACH and animal numbers	8
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment	8
Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing	8
Technical framework for enabling high-quality measurements in new approach methodologies (NAMs)	8
Off to a good start? Review of the predictivity of reactivity methods modelling the molecular initiating event of skin sensitization	8
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment_suppl4	8
Predicting Acute Oral Toxicity Using AcutoX: An Animal Product-Free and Metabolically Relevant Human Cell-Based Test	7
Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study	7
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A	7
The long way from raw data to NAM-based information: Overview on data layers and processing steps	7
Beyond Animal Testing Index: Benchmarking tool for a world beyond animal testing_suppl4	7
Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing	7
E-validation – Unleashing AI for validation	7
Mapping physiology: A systems biology approach for the development of alternative methods in toxicology	6

Developing a global education hub for animal-free innovation_suppl	6
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl3	6
Microphysiological endothelial models to characterize subcutaneous drug absorption_suppl	6
Exploring the synergy of CRISPR and microphysiological systems	6
Protectiveness of NAM-based hazard assessment – which testing scope is required?_suppl1	6
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop	5
A human osteoarthritis mimicking goat cartilage explant-based disease model for drug screening_suppl	5
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting_suppl1	5
Non-animal approaches – Concept, validation, and regulatory acceptance: The fourth Asian Congress of Alternatives to Animal Experiments (4ACAAE) and the seventh Annual Meeting of the Society for Alter	5
3Rs: Progress or a fig leaf?	5
Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity	5
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl6	5
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations	5
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl2	5
Investigation of the publication rate of recent research projects using non-human primates in France	5
Women in Alternatives	4
Designing a national strategy to enable human-relevant research in India: A multistakeholder roundtable meeting report	4
In vitro-based prediction of human plasma concentrations of food-related compounds_suppl1	4
ALTEX Proceedings TIERethik Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment	4
Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment	4
The Alarming Consequences of Workforce Reductions at the FDA, EPA, NIH and CDC in the United States	4
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl3	4
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl4	4
Role of standards and funding in accelerating the development and use of microphysiological systems	4
Material-mediated pyrogens in medical devices: Myth or reality?_suppl2	4
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay	4
The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data	4
Assessment of developmental neurotoxicology-associated alterations in neuronal architecture and function using Caenorhabditis elegans_suppl	4
From cellular perturbation to probabilistic risk assessments	4
Identifying candidate reference chemicals for in vitro testing of the retinoid pathway for predictive developmental toxicity_suppl	3
Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays_suppl	3
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis_suppl1	3
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl1	3
A path forward advancing microphysiological systems	3
Transition to animal-free science: Phasing out animal experiments, phasing in innovation	3
Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells_suppl2	3
Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways	3
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop_suppl	3
Human relevant frontiers in drug safety and efficacy	3
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting	2
Open-source human skin model with an in vivo-like barrier for drug testing_suppl	2
A human iPSC-based in vitro neural network formation assay to investigate neurodevelopmental toxicity of pesticides_suppl2	2
Qualitative and quantitative concentration-response modelling of gene co-expression networks to unlock hepatotoxic mechanisms for next generation chemical safety assessment	2
The SCAHT Adverse Outcome Pathway (AOP)_HUB: A hands-on platform for information exchange, sharing, and developing AOPs	2
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl2	2
Proceedings of a workshop to address animal methods bias in scientific publishing_suppl	2
Next-generation risk assessment of chemicals – Rolling out a human-centric testing strategy to drive 3R implementation: The RISK-HUNT3R project perspective	2
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl2	2
Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations_suppl1	2
Second scientific sessions and international conference of the Society for Alternatives to Animal Testing in Sri Lanka (SAAT-SL)	2

What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl6	2
How to formulate hypotheses and IATA to support grouping and read-across of nanoforms	2
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study_suppl1	2
The need for epigenotoxicity testing	2
Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment	2
Virtual control groups in non-clinical toxicology – A replicability challenge	2
Micro-replace systems	2
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare	2
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl7	2
Comparative evaluation of rat and human in vitro assays for evaluation of thyroid toxicity_suppl1	2
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells_suppl2	2
Ready for regulatory use: NAMs and NGRA for chemical safety assurance	1
Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data_suppl2	1
On the usefulness of animals as a model system (part II): Considering benefits within distinct use domains	1
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study	1
Exploration of the GARDskin applicability domain: Indirectly acting haptens, hydrophobic substances and UVCBs	1
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl1	1
Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays	1
Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)	1
Comparison of human recombinant protein coatings and fibroblast-ECM to Matrigel for induced pluripotent stem cell culture and renal podocyte differentiation_suppl1	1
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis	1
Guidance for Good In Vitro Reporting Standards (GIVReSt) – A draft for stakeholder discussion and background documentation	1
Phase-out planning for animal experimentation: A definition, an argument, and seven action points	1
3 Days for 3Rs 2023: Refinement, reduction, replacement	1
International conference and workshop on “New Approach Methodologies (NAMs) in Pharmacology and Toxicology”	1
Fish Count, Too – The Animal Toll of REACH Aquatic Toxicity Tests_suppl2	1
The turning point: April 2025 marks historic shift in US animal testing policy	1
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl3	1
Review on organ-on-chips for medicines safety assessment: A European regulatory perspective_suppl1	1
Material-mediated pyrogens in medical devices: Myth or reality?_suppl1	1
Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment	1
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A_suppl	1
The benefits of validation of methods for toxicity testing outweigh its costs	1
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells_suppl1	1
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl2	1
Amplifying the impact of kidney microphysiological systems: predicting renal drug clearance using mechanistic modelling based on reconstructed drug secretion_suppl	1
Predictive alternative methods for assessing biocompatibility of dental materials: A NIST-NIDCR workshop report	1
Ways to broaden the awareness, consideration and adoption of new approach methodologies (NAMs)	1
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach_suppl3	1
The impact of biostatistics on hazard characterization using in vitro developmental neurotoxicity assays	1
Towards NAM-based risk assessment for developmental neurotoxic effects, illustrated with chlorpyrifos	1
Integrated skin sensitization assessment based on OECD methods (I): Deriving a point of departure for risk assessment_suppl3	1